Recently at the AAPS annual meeting, the FDA‘s Janet Woodcock discussed what has happened in the last 25 years since AAPS was created and what we should expect in the next 25 years. Woodcock has been with the FDA since 1986 and has seen numerous changes in the industry. The problems in the last two decades had been steadily changing, from drug lag to under testing new drugs. Now some problems that will affect the industry for the next two and a half decades consist of budget cuts that hinder innovation and research to moving towards international standards within the global market. To read the the whole story, go here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.